Clinical characteristics ever and at study enrolment
| Juvenile SpA (n=118) | ||
|---|---|---|
| Clinical manifestations ever before study enrolment* | Clinical manifestations/findings at study enrolment | |
| Peripheral arthritis, n (%) | 113 (95.8) | 89 (75.4) |
| Arthritis joint count (0–64), mean (SD) | 5.1 (5.7) | 2.0 (2.3) |
| Arthritis joint count (0–64), n (%) | ||
| 0 | 5 (4.2) | 27 (23.3) |
| 1 | 15 (12.7) | 34 (29.3) |
| 2–4 | 54 (45.8) | 45 (38.8) |
| 5 or more | 44 (37.3) | 10 (8.6) |
| Enthesitis, n (%) | 52 (44.1) | 19 (16.1) |
| Enthesitis count (0–12), mean (SD) | 0.9 (1.4) | 0.3 (0.8) |
| Enthesitis count (0–12), n (%) | ||
| 0 | 66 (56.9) | 95 (84.1) |
| 1 | 22 (19) | 11 (9.7) |
| 2–4 | 25 (21.6) | 6 (5.3) |
| 5 or more | 3 (2.6) | 1 (0.9) |
| Inflammatory back pain, n (%) | 38 (32.2) | 23 (19.5) |
| Dactylitis, n (%) | 15 (12.7) | 3 (2.5) |
| Tarsitis, n (%) | 11 (9.3) | 10 (8.5) |
| Psoriasis, n (%) | 7 (5.9) | 7 (5.9) |
| Uveitis, n (%) | 8 (6.8) | 3 (2.5) |
| CRP (mg/L), mean (SD) | – | 9 (14.9) |
| CRP ≥5 mg/L, n (%) | – | 48 (50.5) |
| ESR (mm/hour), mean (SD) | – | 16.2 (16.4) |
| ESR >20 mm/hour, n (%) | – | 27 (22.9) |
*According to medical charts.